Abstract
Objective. To study the efficacy of the tolerance of combined regimens of the therapy with high doses of methylprednisolone and methotrexate of the patients with rheumatoid arthritis (RA).
 Materials and methods. The study included 85 patients with RA who underwent inpatient treatment in the Rheumatologic Department of the Clinical Hospital of Dushanbe city for the period 2018-2019. From them, women – 83.2 %, men – 26.8 %; the average duration of the disease is 7.4 years. Extra-articular manifestations of RA were determined in 74.3 % of patients. Against the background of the standard therapy, a regimen of bolus pulse therapy (methylprednisolone 500-1000 mg and methotrexate) was taken for 3 days, which has been followed for observation for a year. The effectiveness of the treatment was assessed according to the American College of Rheumatology (ACR) 20/50/70 criteria. The number of the swollen joints and painful joints (NPV), ESR, C-reactive protein level, and the overall disease activity were determined.
 Results and discussion. After 1 month of therapy, significant positive dynamics were recorded in the all estimated parameters of the RA activity. There was a significant decrease in NPV, as well as the intensity of pain according to the visual analogue scale. During 3 months of observation, 78 % of the observed patients showed improvement and only 11 % of patients had side effects and have not been required of the discontinuation of the treatment.
 Conclusions. The combined pulse therapy of methylprednisolone and methotrexate was an effective and well-tolerated for systemic manifestations of RA and contributed to a significant decrease in RA activity in the shortest time.
Highlights
Extra-articular manifestations of rheumatoid arthritis (RA) were determined in 74.3 % of patients
Against the background of the standard therapy, a regimen of bolus pulse therapy was taken for 3 days, which has been followed for observation for a year
The effectiveness of the treatment was assessed according to the American College of Rheumatology (ACR) 20/50/70 criteria
Summary
Исследование эффективности и переносимости комбинированных режимов терапии высокими дозами метилпреднизолона и метотрексата у больных ревматоидным артритом (РА). В исследование включено 85 больных РА, проходивших стационарное лечение в ревматологическом отделении городской клинической больницы г. Из них женщин – 83,2 %, мужчин – 26,8 %; средняя продолжительность заболевания – 7,4 года. В дополнение к стандартному лечению пациентам назначали болюсное введение пульс-терапии (метилпреднизолона 500-1000 мг и метотрексата) в течение 3 дней с последующим наблюдением в течение года. На протяжении 3-месячного наблюдения у 78 % больных отмечалось улучшение и лишь у 11 % пациентов – побочные эффекты, которые не требовали прекращения лечения. Сочетанная пульс-терапия метилпреднизолоном и метотрексатом явилась эффективной и хорошо переносимой при системных проявлениях РА, поскольку способствовала в кратчайшие сроки значимому снижению активности заболевания.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have